Filter by patients with: All

What is MS Phase III Arbaclofen Study?

Category: Others

false

There are two MS Phase III Arbaclofen Studies: One is a dose escalation study to examine the safety and efficacy of Arbaclofen in MS patients with spasticity. NCT01844232 The other study is looking at the long term safety and efficacy of Arbaclofen in MS. NCT01360489

See patients taking MS Phase III Arbaclofen Study

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Muscle spasms 1 1
  • Major
  • Moderate
  • Slight
  • None
  • Can't tell
See 1 patient that have used MS Phase III Arbaclofen Study

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 0
Mild 0
None 1

Commonly reported side effects and conditions associated with MS Phase III Arbaclofen Study

Side effect Patients Percentage

Why patients stopped taking MS Phase III Arbaclofen Study

Multiple reasons could be selected

Reason Patients Percentage
Course of treatment ended 1
See 1 patient who's stopped using MS Phase III Arbaclofen Study

Duration

Stopped using MS Phase III Arbaclofen Study

Duration Patients Percentage
1 - 2 years 1
Adherence
Adherence Evaluations Percentage
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Last updated:
There are no evaluations for MS Phase III Arbaclofen Study.